Compare
Armata Pharmaceuticals, Inc. vs Alpha Cognition Inc. vs Protalix BioTherapeutics, Inc. vs Fennec Pharmaceuticals Inc.
| Latest fiscal year | Armata Pharmaceuticals, Inc. ARMP | Alpha Cognition Inc. ACOG | Protalix BioTherapeutics, Inc. PLX | Fennec Pharmaceuticals Inc. FENC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $10.22M | $52.74M | $44.64M |
| Revenue growth (YoY) | n/a | n/a | -1.2% | -6.1% |
| Gross margin | n/a | 94.1% (computed) | 48.8% (computed) | n/a |
| Operating margin | n/a | -221.7% | -10.4% | -14.1% |
| Net margin | n/a | -202.2% | -12.5% | -21.8% |
| Net income | -$173.80M | -$20.67M | -$6.60M | -$9.74M |
| EPS (Diluted) | -$4.80 | -$1.18 | -$0.08 | -$0.34 |
| Operating cash flow | -$25.76M | -$20.38M | -$11.99M | -$12.47M |
| Free cash flow | -$26.30M | -$20.67M | -$13.63M | n/a |
| Cash & equivalents | $8.69M | $66.05M | $14.68M | $36.79M |
| Total assets | $76.88M | $79.73M | $82.35M | $70.55M |
| Total liabilities | $295.48M | $17.20M | $34.12M | $35.08M |
| Shareholders' equity | -$218.60M | $62.53M | $48.23M | $35.47M |
| Return on year-end equity | n/a | -33.1% | -13.7% | -27.5% |
| Shares outstanding | 36.43M | 21.74M | 80.43M | 34.16M |
Revenue, most recent five fiscal years
| Fiscal year | Armata Pharmaceuticals, Inc. | Alpha Cognition Inc. | Protalix BioTherapeutics, Inc. | Fennec Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | n/a | $10.22M Ended 2025-12-31 | $52.74M Ended 2025-12-31 | $44.64M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $53.40M Ended 2024-12-31 | $47.54M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $65.49M Ended 2023-12-31 | $21.25M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $47.64M Ended 2022-12-31 | $1.53M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $38.35M Ended 2021-12-31 | n/a |